Gonorrhea, the second most reported bacterial sexually transmitted infection (STI), affected approximately 82 million people globally in 2020. The incidence is higher in low and middle-income countries where the burden of drug resistance is most pronounced. Gonorrhea can lead to severe health complications such as pelvic inflammatory disease, chronic pelvic pain, and infertility. Since not all patients show symptoms, the true burden of the disease is likely much greater than reported cases suggest. To combat this, rapid and advanced diagnostics are crucial for detecting drug-resistant bacterial infections early and guiding effective treatment. Now, a portable PCR platform with high multiplexing capabilities is being developed to identify multiple pathogenic bacterial targets and their antibiotic susceptibility, thus aiding in point-of-care treatment decisions. Prompt Diagnostics (Baltimore, MD, USA) has been awarded USD 1 million by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X, Boston, MA, USA) to further the development of its portable PCR ...
Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements from a small blood sample to predict a variety of diseases. In the research, published in Nature Medicine, which was carried out as part of an international partnership involving Queen Mary University of London (London, UK), the investigators used data from the UK Biobank Pharma Proteomics Project (UKB-PPP). This project represents the largest proteomic study to date, analyzing around 3,000 plasma proteins from over 40,000 randomly selected UK Biobank participants. These protein measurements are linked to detailed electronic health records. The researchers applied sophisticated analytical techniques to identify a specific ‘signature’ of 5 to 20 key proteins for predicting each disease. They discovered that these protein ‘signatures’ can predict the onset of 67 different diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron ...
Not long after pulling a last-minute plug on a $232m initial public offering (IPO) on Nasdaq, Telix Pharmaceuticals has raised $398m (A$600m) via the issue of convertible bonds. The bonds, which are convertible into ordinary shares, will yield a 2% – 2.75% interest, the radiopharmaceutical specialist said in a 23 July press release. The maturity date is set for five years from now, at the end of July 2029. Australia-based Telix said it intends to list the convertible bonds on the Official List of Singapore Exchange Securities Trading Limited (SGX-ST). While Telix had been planning on going public on Nasdaq earlier this year, the company U-turned on the IPO citing market conditions at the time. Telix had been on course to raise $232m in the listing, though the company maintained that the decision was not “predicated on the need to raise capital”. Instead, the convertible bonds bring low-cost financing to ...
Organiser: Vietnam Ministry of Health Time: December 5-7, 2024 address:NO.91 TRAN HUNG DAO STR., HOAN KIEM DIST., HANOI, VIETNAM Exhibition hall:Hanoi International Exhibition Center Product range: Ⅰ. Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical healthcare products and devices, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments Ⅱ. Analytical Instruments: Optical analysis instruments, mass spectrometers, spectrometers, chromatographs, spectrographs, spectrum analyzers, electrochemical analysis instruments, ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, component analysis instruments, injection analysis instruments, and other general analytical instruments Ⅲ. Laboratory Equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, microscopes, optical image processing, electronic measuring instruments, ...
Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting system via a device known as a spectrometer. When utilized on complex biofluids like blood plasma, this physico-chemical technique provides in-depth molecular insights, indicating its potential for medical diagnostics. Despite its established role in chemistry and industry, infrared spectroscopy has yet to become a standard tool in medical diagnostics. To tackle this issue, scientists have developed a diagnostic tool that employs infrared light and machine learning to identify multiple health conditions in just one measurement at the population level. The team from the BIRD group at Ludwig Maximilian University of Munich (LMU, Munich, Germany) had previously worked on methods to measure human plasma. In their most recent study, they introduced infrared molecular fingerprinting to a naturally diverse group, analyzing blood from ...
Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has been conducted through histological staining (immunohistochemistry), which involves identifying specific markers that categorize tumors into distinct subtypes. Recently, high-throughput transcriptomic profiling has transformed the way breast cancer subtypes are identified by analyzing gene activity in cancer cells through the total messenger RNAs present, which correspond to gene sequences and are used by ribosomes to synthesize proteins. Transcriptomic profiling utilizes RNA sequencing (RNAseq), a rapidly evolving molecular biology technique that sequences RNA strands efficiently. As RNA sequencing becomes more affordable, it holds the potential for routine clinical integration to aid in diagnosis and treatment decisions. However, its application is currently limited by the requirement for processing large sample batches simultaneously and difficulties in comparing samples across different platforms. Now, scientists have developed a computational tool that ...
Researchers are advancing the development of an exhaled-breath test to detect lung diseases, including lung cancer. Two pivotal studies published in the Journal of Extracellular Vesicles detail their success in isolating and analyzing lung biomarkers from human breath and utilizing animal models to further explore and possibly identify crucial markers for the early and non-invasive detection of metastatic lung tumors. While substantial efforts are needed to identify a spectrum of biomarkers and validate their clinical relevance for human patients, these publications provide a scientific framework for continued research. The research by scientists at Hackensack Meridian Health (Edison, NJ, USA) focuses on capturing and characterizing extracellular vesicles (EVs), nanoparticles released by cells into fluids like blood and serum. Cancer cells release these particles abundantly, making them prime targets for early disease detection. The researchers have initiated biomarker discovery projects for several cancers, including lung, prostate, cervical, and bladder cancers, using liquid ...
Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically colonize patients, facilitating its spread within these settings. Known to be a significant risk factor for invasive infections, C. auris is associated with high mortality rates and is resistant to many antifungal medications typically used for treatment. It has been responsible for outbreaks in over 35 countries in the past decade, marking it as a critical antimicrobial resistance threat. Given this, it is crucial to screen for C. auris to enable the timely implementation of contact precautions and infection control measures that can curb its spread within healthcare facilities and prevent potential outbreaks. Traditional testing methods can take days to yield results and often require sending samples to a reference laboratory. Now, a real-time polymerase chain reaction (RT-PCR) assay for ...
Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide. Many adults avoid routine blood tests due to their complexity and the long wait times for results, which can lead to delayed interventions or missed diagnoses, resulting in substantial avoidable costs. Now, a groundbreaking diagnostic platform is set to transform the existing global infrastructure by providing lab-accurate, actionable test results that aid in the early detection and prevention of chronic conditions. Truvian Health (San Diego, CA, USA) has developed an automated benchtop system that allows simple, accurate, and comprehensive routine blood tests to be conducted directly in clinics, doctor’s offices, and pharmacies. Utilizing patented technologies and intelligent integration, Truvian’s compact device offers a convenient and economical alternative to traditional off-site labs, delivering quick, lab-accurate results from just a small blood sample, ...
By Mike Hollan Ripston discusses the Biospecimen Management Consortium and how its working to develop best practices for driving sample excellence. Slope recently announced the launching of the Biospecimen Management Consortium (BMC), and new group focused on ensuring sample excellence in clinical trials. The group’s executive director, Amy Ripston, spoke with Pharmaceutical Executive about the group, it’s goals, and the importance of this work in the modern world. Pharmaceutical Executive: What are the goals of the BMC? Amy Ripston: The Biospecimen Management Consortium (BMC) was formed to elevate industry-wide excellence in sample management, raise the bar for data integrity and quality, and enable the future of complex clinical research. To accomplish this, the BMC will drive a variety of initiatives aimed at developing best practices and industry standards, streamlining biospecimen lifecycle operations and data management, and influencing regulatory policy. These initiatives will take a critical look at existing processes including, ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.